RTW vs. N91, WTAN, BRW, ATT, SNN, BHMU, JTC, PIN, FGT, and BNKR
Should you be buying RTW Biotech Opportunities stock or one of its competitors? The main competitors of RTW Biotech Opportunities include Ninety One Group (N91), Witan Investment Trust (WTAN), Brewin Dolphin (BRW), Allianz Technology Trust (ATT), Sanne Group (SNN), BH Macro USD (BHMU), JTC (JTC), Pantheon International (PIN), Finsbury Growth & Income (FGT), and The Bankers Investment Trust (BNKR). These companies are all part of the "asset management" industry.
RTW Biotech Opportunities vs. Its Competitors
Ninety One Group (LON:N91) and RTW Biotech Opportunities (LON:RTW) are both small-cap financial services companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, community ranking, analyst recommendations, institutional ownership and media sentiment.
RTW Biotech Opportunities has a net margin of 664.38% compared to Ninety One Group's net margin of 26.24%. Ninety One Group's return on equity of 42.90% beat RTW Biotech Opportunities' return on equity.
Ninety One Group received 1 more outperform votes than RTW Biotech Opportunities when rated by MarketBeat users. However, 100.00% of users gave RTW Biotech Opportunities an outperform vote while only 13.33% of users gave Ninety One Group an outperform vote.
RTW Biotech Opportunities has higher revenue and earnings than Ninety One Group. RTW Biotech Opportunities is trading at a lower price-to-earnings ratio than Ninety One Group, indicating that it is currently the more affordable of the two stocks.
Ninety One Group currently has a consensus price target of GBX 173, suggesting a potential upside of 0.05%. Given Ninety One Group's stronger consensus rating and higher possible upside, equities analysts plainly believe Ninety One Group is more favorable than RTW Biotech Opportunities.
In the previous week, RTW Biotech Opportunities had 2 more articles in the media than Ninety One Group. MarketBeat recorded 2 mentions for RTW Biotech Opportunities and 0 mentions for Ninety One Group. RTW Biotech Opportunities' average media sentiment score of 1.13 beat Ninety One Group's score of 0.00 indicating that RTW Biotech Opportunities is being referred to more favorably in the news media.
Ninety One Group has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, RTW Biotech Opportunities has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
26.8% of Ninety One Group shares are held by institutional investors. Comparatively, 3.9% of RTW Biotech Opportunities shares are held by institutional investors. 58.3% of Ninety One Group shares are held by company insiders. Comparatively, 16.2% of RTW Biotech Opportunities shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Ninety One Group beats RTW Biotech Opportunities on 11 of the 17 factors compared between the two stocks.
Get RTW Biotech Opportunities News Delivered to You Automatically
Sign up to receive the latest news and ratings for RTW and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RTW Biotech Opportunities Competitors List
Related Companies and Tools
This page (LON:RTW) was last updated on 6/15/2025 by MarketBeat.com Staff
Buy RTW Stock Free RTW Stock Alerts